Percheron Therapeutics Secures $2.2 Million for Phase II Development of HMBD-002
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has raised $2.2 million through a fully subscribed entitlement offer to fund its phase II trial for HMBD-002, a cancer immunotherapy targeting VISTA. The funding includes $800,000 from existing shareholders and $1.4 million from new investors, with proceeds expected to support development in 2026.
Topics: equity offering fundraising pharmaceutical development phase II trial